Table 5 Significantly associated clinical characteristics

Iwai et al. [19]

Dose < 18Gy

N/A

Infratentorial location

N/A

Jagannathan et al. [27]

Greater treated volume

N/A

N/A

Systemic progression

Karlovits et al. [31]

N/A

N/A

N/A

>1 intracranial metastasis

Extracranial disease

Jensen et al. [15]

Preop diameter > 3 cm

Dose <35Gy

N/A

N/A

Rwigema et al. [20]

Greater PTV

N/A

N/A

Age

RPA score

Choi et al. [21]

N/A

Melanoma histology

N/A

KPS

Preop diameter

Ogiwara et al. [33]

N/A

N/A

N/A

Extracranial metastases

Prabhu et al. [22]

Larger PTV volume

N/A

N/A

N/A

Marginal dose <18 Gy

Brennan et al. [34]

NSCLC histology

Infratentorial location

N/A

N/A

Preop diameter > 3 cm

Dural/ pial involvement

Hartford et al. [35]

Preop diameter ≥ 2 cm

Preop diameter ≥ 2 cm

N/A

GPA ≤1

Ojerholm et al. [18]

Preop diameter ≥ 3 cm

N/A

Breast histology

New diagnosis or untreated primary

Infratentorial location

Ling et al. [25]

N/A

Uncontrolled systemic disease

N/A

Increasing no. metastases

Melanoma histology

Uncontrolled systemic disease

Increasing no. brain metastases

Present study

N/A

Synchronous metastases

N/A

Male gender